Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide

Anna Angona; Beatriz Bellosillo; Alberto Alvarez-Larrán; Luz Martínez-Avilés; Laura Camacho; Silvia Pairet; Maria Concepción Fernández-Rodriguez; Àgueda Ancochea; Carles Besses

doi:10.1016/j.leukres.2013.03.013

Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide

Anna Angona, Beatriz Bellosillo, Alberto Alvarez-Larrán, Luz Martínez-Avilés, Laura Camacho, Silvia Pairet, Maria Concepción Fernández-Rodriguez, Àgueda Ancochea, Carles Besses

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

21 Citations (Scopus)

Abstract

JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect. © 2013 Elsevier Ltd.

Original language	English
Pages (from-to)	917-921
Journal	Leukemia Research
Volume	37
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2013.03.013
Publication status	Published - 1 Aug 2013

Keywords

Essential thrombocythemia
Hydroxycarbamide
Molecular response
Polycythemia vera

Access to Document

10.1016/j.leukres.2013.03.013

Cite this

@article{c95fc4bd677848908d01d458dab247cb,

title = "Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide",

abstract = "JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect. {\textcopyright} 2013 Elsevier Ltd.",

keywords = "Essential thrombocythemia, Hydroxycarbamide, Molecular response, Polycythemia vera",

author = "Anna Angona and Beatriz Bellosillo and Alberto Alvarez-Larr{\'a}n and Luz Mart{\'i}nez-Avil{\'e}s and Laura Camacho and Silvia Pairet and Fern{\'a}ndez-Rodriguez, {Maria Concepci{\'o}n} and {\`A}gueda Ancochea and Carles Besses",

year = "2013",

month = aug,

day = "1",

doi = "10.1016/j.leukres.2013.03.013",

language = "English",

volume = "37",

pages = "917--921",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

TY - JOUR

T1 - Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide

AU - Angona, Anna

AU - Bellosillo, Beatriz

AU - Alvarez-Larrán, Alberto

AU - Martínez-Avilés, Luz

AU - Camacho, Laura

AU - Pairet, Silvia

AU - Fernández-Rodriguez, Maria Concepción

AU - Ancochea, Àgueda

AU - Besses, Carles

PY - 2013/8/1

Y1 - 2013/8/1

N2 - JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect. © 2013 Elsevier Ltd.

AB - JAK2V617F allele burden was prospectively measured in polycythemia vera (PV, n=52) and essential thrombocythemia (ET, n=39) patients receiving hydroxycarbamide (HC) and analyzed according to JAK2 46/1 haplotype and genotype of SLC14A1, SLC14A2 and ARG2 urea transporters. Molecular response (MR) was obtained in 68.7% and 38.9% of PV patients with GG and AA or GA genotype in SLC14A2, respectively (p=0.07). No significant differences were observed neither in PV nor in ET according to JAK2 46/1 haplotype, SLC14A1 and ARG2. In conclusion, JAK2 46/1 haplotype does not influence MR in HC treated patients and urea transporters polymorphisms display a minimal effect. © 2013 Elsevier Ltd.

KW - Essential thrombocythemia

KW - Hydroxycarbamide

KW - Molecular response

KW - Polycythemia vera

U2 - 10.1016/j.leukres.2013.03.013

DO - 10.1016/j.leukres.2013.03.013

M3 - Article

SN - 0145-2126

VL - 37

SP - 917

EP - 921

JO - Leukemia Research

JF - Leukemia Research

IS - 8

ER -

Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide

Abstract

Keywords

Access to Document

Fingerprint

Cite this